St. Jude seeks damages from Occlutech
St. Jude Medical, through its recent $1.3 billion acquisition of AGA Medical, has filed lawsuits against Occlutech for patent infringement. The suits, which involve a total of three patents and seek injunctive relief and monetary damages, were filed in Germany and the U.K. at the District Court of Dusseldorf and the High Court of Justice, Chancery Division, Patents Court, respectively.

The patent infringement suits allege that products distributed by Occlutech, namely the company’s atrial septal defect and patent foramen ovale closure/occlusion devices, infringe on key patents used for the St. Jude's Amplatzer occlusion device platform. The platform, which is comprised of nitinol-based occlusion devices and accessories, offers minimally invasive transcatheter treatments for the closure of structural defects found in a patient’s heart.

“St. Jude Medical values the innovations we bring to the industry and will closely protect our intellectual property,” said Frank Callaghan, president of the cardiovascular division of the St. Paul, Minn.-based St. Jude.

AGA Medical has been engaged in litigation against Occlutech since 2006.